SCHEMBL5019767

SCHEMBL5019767

CC(C)(CCNC(=O)C1(N)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ MMP1 P03956 1/20 0.42
▸ MMP2 P08253 1/20 0.42
▸ MMP9 P14780 1/20 0.42
▸ MMP8 P22894 1/20 0.42
▸ MMP13 P45452 1/20 0.42
▸ CYP3A4 P08684 4/20 0.42
▸ CYP2C19 P33261 3/20 0.42
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ TP53BP1 Q12888 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ NR1I2 O75469 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15647201 0.96 CA1 (0.41) CA1CA2MMP1MMP2MMP9
SCHEMBL15645087 0.95 KMT2A (0.44) CA1CA2MMP1MMP2MMP9
SCHEMBL15646234 0.93 MMP2 (0.42) CA1CA2MMP1MMP2MMP9
SCHEMBL5019768 0.92 CYP3A4 (0.40) CA1CA2MMP1MMP2MMP9
SCHEMBL15646177 0.84 CYP3A4 (0.47) CA1CA2MMP1MMP2MMP9
SCHEMBL1498553 0.83 CA1 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL15647079 0.83 KMT2A (0.43) CA1CA2MMP1MMP2MMP9
Hydrochloric Acid SCHEMBL4541555 0.82 KMT2A (0.42) CA1CA2MMP1MMP2MMP9
SCHEMBL15646695 0.81 KMT2A (0.40) CA1CA2MMP1MMP2MMP9
SCHEMBL5019854 0.81 CNR2 (0.51) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 — — US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 — — US disclosed
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (US) 2014-04-24 — — US disclosed
WO-2012061926-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113898-A1 BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1S, KCNN4 CA1 1399/4885CA2 149/4885MMP1 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback